Rapid analytical tryptic mapping of a recombinant chimeric monoclonal antibody and method validation challenges

被引:14
作者
Kannan, K
Mulkerrin, MG
Zhang, M
Gray, R
Steinharter, T
Sewerin, K
Baffi, R
Harris, R
Karunatilake, C
机构
[1] Genentech Inc, Dept Qual Control Clin Dev, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA
关键词
recombinant protein; monoclonal antibody; identity; tryptic mapping; reversed-phase HPLC; method validation;
D O I
10.1016/S0731-7085(97)00179-9
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid and reproducible analytical tryptic mapping method was developed as an identity test for a recombinant chimeric monoclonal antibody for lot release testing. The unfolding, reduction, carboxymethylation, trypsin digestion, and reversed-phase (RP) HPLC steps were optimized to provide a reproducible method. The optimized method requires 30 min for unfolding the protein, 30 min for carboxymethylation, 4 h for digestion with TPCK-trypsin and 140 min for RPHPLC analysis. The total time required is less than 8 h compared to conventional procedures, which must be performed over several days. The optimized method was validated for its precision, recovery, specificity, and robustness. The precision of the method was determined by repeatability and intermediate precision experiments. Relative standard deviation (RSD) values were less than or equal to 10% for the relative peak areas of marker peaks. The mean recovery of these marker peaks was 88.4%. The specificity was demonstrated by the unique tryptic mapping patterns obtained compared with several other monoclonal antibodies. Robustness was demonstrated by the relative insensitivity of the tryptic map to small deliberate changes in key method parameters. Excessive relative peak area variability observed for one peak (RSD 52%) was traced to adsorption to glass autosampler vials. This variability was substantially reduced (RSD 11%) by substituting polypropylene autosampler vials. The data demonstrate that this method may be applicable to a wide range of pharmaceutically relevant monoclonal antibodies. Published by Elsevier Science B.V.
引用
收藏
页码:631 / 640
页数:10
相关论文
共 12 条
  • [1] Validation of peptide mapping for protein identity and genetic stability - Biologics and biotechnology section, pharmaceutical research and manufacturers of America
    Allen, D
    Baffi, R
    Bausch, J
    Bongers, J
    Costello, M
    Dougherty, J
    Federici, M
    Garnick, R
    Peterson, S
    Riggins, R
    Sewerin, K
    Tuls, J
    [J]. BIOLOGICALS, 1996, 24 (03) : 255 - 275
  • [2] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [3] BURSTYN DG, 1991, BIOPHARM TECHNOL FEB, P22
  • [4] Garnick R L, 1992, Dev Biol Stand, V76, P117
  • [5] HANCOCK WS, 1995, NEW METHODS PEPTIDE
  • [6] HARRIS RJ, 1993, BIO-TECHNOL, V11, P1293
  • [7] Hoff ER, 1996, METHOD ENZYMOL, V271, P51
  • [8] IFPMA, 1995, FED REGISTER, V60, P11260
  • [9] KAT E, 1996, PROTEIN SCI S1, V5, P138
  • [10] IDENTIFICATION OF SITES OF DEGRADATION IN A THERAPEUTIC MONOCLONAL-ANTIBODY BY PEPTIDE-MAPPING
    KROON, DJ
    BALDWINFERRO, A
    LALAN, P
    [J]. PHARMACEUTICAL RESEARCH, 1992, 9 (11) : 1386 - 1393